Zerion Pharma A/S appoints Mads Aaboe Jensen as Vice President, Business Development
Comunicato Precedente
Comunicato Successivo
Mads Aaboe Jensen joins ZERION with more than 20 years of experience at the crossroads of science and business. Prior to joining ZERION, he was VP of Business Development and Innovation at Scandion Oncology A/S, and before that he was leading RNA molecule external innovation at Roche. He is an established life science innovator and holds a MSc degree in Molecular Biology and a PhD degree in Medicine from Aarhus University. Furthermore, he has completed an executive CBL management & business education program at Henley Business School.
About Zerion Pharma A/S
ZERION develops its own proprietary drug formulations and offers its Dispersome® technology platform to established pharma companies as a means to solve their challenging drug solubility problems. By applying ZERION's technology, the solubility of poorly soluble compounds may be greatly enhanced, which improves their oral bioavailability and thereby therapeutic outcomes for the patients.
ZERION was established in 2019 as a spin-out from the University of Copenhagen based on almost a decade of research.
For more information, please visit www.zerion.eu or contact:
Ole Wiborg, CEO, Mobile: +45 40 96 80 18, E-mail: info@zerion.eu
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/zerion-pharma-as-appoints-mads-aaboe-jensen-as-vice-president-business-development-301915743.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
